FC Breedveld, MH Weisman, AF Kavanaugh, SB … - Arthritis Care & Research - interscience.wiley.com Dr. Breedveld has received consulting fees or honoraria (less than $10,000 per
year) from Centocor, Schering-Plough, Amgen/Wyeth, and Abbott. Dr. Weisman has
received consulting fees or honoraria (less than $10,000 per year) from ... Cited by 435 - Related articles - BL Direct - All 6 versions
T Möttönen, P Hannonen, M Korpela, M … - Arthritis Care & Research - interscience.wiley.com In the FIN-RACo (FINnish Rheumatoid Arthritis Combination therapy) trial, 195
patients with recent-onset RA (median duration 6 months) were randomly assigned
to receive either 1) a combination of DMARDs (sulfasalazine, methotrexate, ... Cited by 164 - Related articles - BL Direct - All 4 versions
I Amgen - Arthritis Care & Research - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 160 - Related articles - BL Direct - All 3 versions
KP Machold, TA Stamm, GJM Eberl, VK Nell, … - Journal of Rheumatology, 2002 - jrheum.org From the Department of Rheumatology, University of Vienna; Centre for Diagnosis
and Treatment of Rheumatic Diseases, Lainz Hospital, Vienna; Department of
Internal Medicine 5, Wilhelminenspital, Vienna; and Department of ... Cited by 91 - Related articles - BL Direct - All 9 versions
T Sokka, T Pincus - J Rheumatol, 2003 - jrheum.org From the Division of Rheumatology and Immunology, Vanderbilt University School
of Medicine, Nashville, Tennessee, USA. Supported in part by grants from
Aventis, Amgen, Pharmacia, the Jack C. Massey Foundation, the Academy of ... Cited by 90 - Related articles - All 9 versions
- ►oxfordjournals.org T Pincus, G Ferraccioli, T Sokka, A Larsen, R … - Rheumatology, 2002 - Br Soc Rheumatology Earlier reports, including a comprehensive 1983 review, had indicated that
slowing of radiographic progression was relatively unusual in treatment of
rheumatoid arthritis (RA) using traditional disease modifying ... Cited by 88 - Related articles - BL Direct - All 5 versions
T Pincus, T Sokka, H Kautiainen, A … - Arthritis Care & Research - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 79 - Related articles - All 3 versions
JA RINDFLEISCH, D MULLER - Hand - aafp.org Rheumatoid arthritis is a chronic inflammatory disease characterized by
uncontrolled proliferation of synovial tissue and a wide array of multisystem
comorbidities. Prevalence is estimated to be 0.8 percent worldwide, with ... Cited by 67 - Related articles - All 13 versions
PA Calabresi, JL Wilterdink, JM Rogg, P … - Neurology, 2002 - AAN Enterprises Within the past 10 years, three immunomodulatory agents—interferon ß-1b
(IFNß-1b; Betaseron, Berlex Laboratories, Richmond, CA), interferon ß-1a
(IFNß-1a; Avonex, Biogen, Cambridge, MA), and glatiramer acetate ... Cited by 63 - Related articles - BL Direct - All 4 versions
